retatrutide triple agonist glp-1 gip glucagon #retatrutide is a novel peptide at the receptor, receptor, and receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter https://t.co/duYwW0EcmF Retatrutide is a triple-agonist drug

For example, in the SELECT cardiovascular outcome trial studying people with obesity, the extent of weight loss did not correlate with the effects of the drug to reduce heart attack, stroke, and cardiovascular death . Also, another long-acting GLP-1 therapy, albiglutide, [was] withdrawn from the market owing to modest efficacy for reduction of glucose and body weight in people with T2D

avoid freezethaw cycles of reconstituted solution

GLP-1 medications are medications that mimic or activate incretin hormone pathways in the body

These medications are compounded to provide the same active ingredients as the brand names, ensuring effective treatment without the high costs

Most peptides discussed in muscle research influence growth hormone pathways rather than directly increasing testosterone